Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

In vivo regulation of hTERT expression and telomerase activity by androgen.

Guo C, Armbruster BN, Price DT, Counter CM.

J Urol. 2003 Aug;170(2 Pt 1):615-8.

PMID:
12853842
2.

Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development.

Moehren U, Papaioannou M, Reeb CA, Grasselli A, Nanni S, Asim M, Roell D, Prade I, Farsetti A, Baniahmad A.

FASEB J. 2008 Apr;22(4):1258-67. Epub 2007 Nov 8.

PMID:
17991730
3.

Androgen regulation of parathyroid hormone-related peptide production in human prostate cancer cells.

Pizzi H, Gladu J, Carpio L, Miao D, Goltzman D, Rabbani SA.

Endocrinology. 2003 Mar;144(3):858-67.

PMID:
12586762
4.

Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.

Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM.

Cancer Res. 2000 Nov 1;60(21):6134-41.

5.

The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells.

Geier R, Adler S, Rashid G, Klein A.

Prostate. 2010 Sep 1;70(12):1307-12. doi: 10.1002/pros.21166.

PMID:
20623632
6.

Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.

Liu S, Qi Y, Ge Y, Duplessis T, Rowan BG, Ip C, Cheng H, Rennie PS, Horikawa I, Lustig AJ, Yu Q, Zhang H, Dong Y.

Mol Cancer Ther. 2010 Jul;9(7):2016-25. doi: 10.1158/1535-7163.MCT-09-0924. Epub 2010 Jun 22.

7.

Modulation of human telomerase reverse transcriptase in hepatocellular carcinoma.

Chen CJ, Kyo S, Liu YC, Cheng YL, Hsieh CB, Chan DC, Yu JC, Harn HJ.

World J Gastroenterol. 2004 Mar 1;10(5):638-42.

8.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.

PMID:
12539223
9.

Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity.

Ouchi H, Ishiguro H, Ikeda N, Hori M, Kubota Y, Uemura H.

Int J Urol. 2005 Jan;12(1):73-80.

10.

Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.

Zaia A, Fraizer GC, Piantanelli L, Saunders GF.

Anticancer Res. 2001 Jan-Feb;21(1A):1-10.

PMID:
11299720
11.
12.

Signaling through estrogen receptors modulates telomerase activity in human prostate cancer.

Nanni S, Narducci M, Della Pietra L, Moretti F, Grasselli A, De Carli P, Sacchi A, Pontecorvi A, Farsetti A.

J Clin Invest. 2002 Jul;110(2):219-27.

13.

Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.

Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A.

Cancer J. 2000 Jul-Aug;6(4):220-33.

PMID:
11038142
14.

Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events.

Sirotnak FM, She Y, Khokhar NZ, Hayes P, Gerald W, Scher HI.

Mol Carcinog. 2004 Nov;41(3):150-63.

PMID:
15390081
15.

NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.

Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ.

Cancer Res. 2004 Aug 1;64(15):5489-95.

16.

A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter.

Komata T, Koga S, Hirohata S, Takakura M, Germano IM, Inoue M, Kyo S, Kondo S, Kondo Y.

Int J Oncol. 2001 Nov;19(5):1015-20.

PMID:
11605003
17.

Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells.

Suenaga M, Soda H, Oka M, Yamaguchi A, Nakatomi K, Shiozawa K, Kawabata S, Kasai T, Yamada Y, Kamihira S, Tei C, Kohno S.

Int J Cancer. 2002 Feb 10;97(5):621-5.

18.

Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.

Braunstein I, Cohen-Barak O, Shachaf C, Ravel Y, Yalon-Hacohen M, Mills GB, Tzukerman M, Skorecki KL.

Cancer Res. 2001 Jul 15;61(14):5529-36.

19.

Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens.

Granchi S, Brocchi S, Bonaccorsi L, Baldi E, Vinci MC, Forti G, Serio M, Maggi M.

Prostate. 2001 Dec 1;49(4):267-77.

PMID:
11746273
20.

Molecular mechanisms of ceramide-mediated telomerase inhibition in the A549 human lung adenocarcinoma cell line.

Ogretmen B, Kraveka JM, Schady D, Usta J, Hannun YA, Obeid LM.

J Biol Chem. 2001 Aug 31;276(35):32506-14. Epub 2001 Jul 5.

Supplemental Content

Support Center